Immatics Announced At ESMO Saturday, Updated Phase 1b IMA402 Data Showing 32% Confirmed Response Rate, 12.5-Month Median Duration Of Response And 91% One-Year Overall Survival Rate In Advanced Melanoma Patients With High PRAME Expression

뉴스 본문을 불러오고 있어요.

Immatics Announced At ESMO Saturday, Updated Phase 1b IMA402 Data Showing 32% Confirmed Response Rate, 12.5-Month Median Duration Of Response And 91% One-Year Overall Survival Rate In Advanced Melanoma Patients With High PRAME Expression | 웨이프 WAPE

Immatics Announced At ESMO Saturday, Updated Phase 1b IMA402 Data Showing 32% Confirmed Response Rate, 12.5-Month Median Duration Of Response And 91% One-Year Overall Survival Rate In Advanced Melanoma Patients With High PRAME Expression

기사 요약

관련 종목

댓글 —